Chief exec of Nottingham life sciences firm steps down

Geoffrey Hamilton-Fairley

The founder of Nottingham-based Oncimmune, the early-detection cancer company, is stepping down from his role as chief executive

The company has appointed Adam Hill as its new CEO, with founder Geoffrey Hamilton-Fairley moving into a new role as vice chairman.

Hill joined Oncimmune as chief medical officer and chief scientific officer and executive director earlier this year from McLaren Applied Technologies and has been leading both the R&D team and a strategic review of the company.

Hamilton-Fairley, an early pioneer in the field of cancer immunodiagnostics, joined Oncimmune in 2005 as it was established as a spin out of the University of Nottingham, and led the company’s transition to a commercial phase company with the launch in the US of two early detection blood based tests in lung and liver cancer. He also led the geographic expansion with collaborative partnerships in China, Europe and the Middle East.

Hamilton-Fairley said: “It has been a great experience leading Oncimmune from its spin out from Nottingham University and a team of dedicated colleagues and research collaborators who have been working together to transform the treatment of cancer through immunodiagnostics leading to early detection and improved care and outcomes.

“The company is well positioned for an exciting future and it is now time to transition to new leadership who will take our products and technology through clinical development and broad global commercialisation, and Adam has demonstrated that he is the ideal leader to deliver the next phase of Oncimmune’s growth. My thanks and appreciation to the extended Oncimmune team and partners, past and present.”